Xencor Inc (XNCR): Operating Income
-$177.50M
Year ended 2025-12-31
-$216.08M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$177.50M | n/m | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | -$178.41M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$132.36M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$82.47M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $43.77M | n/m | 2025-02-24, From 2021-01-01 |
| 2020-12-31 | -$76.80M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $13.82M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$79.37M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | -$43.12M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $44.04M | n/c | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | -$18.34M | n/m | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | -$16.46M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$10.52M | n/m | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | -$6.23M | n/a | 2015-02-23, From 2012-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Xencor Inc (XNCR) | 2025-12-31 | -$177.50M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$17.25M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $11.49M | -28.9% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$124.86M | n/m |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$90.71M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | -$62.94M | n/m |
| Zymeworks Inc. (ZYME) | 2025-12-31 | -$92.55M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $49.11M | +150.6% |
| Macrogenics Inc (MGNX) | 2025-12-31 | -$72.84M | n/m |
Compare XNCR, LFCR, GYRE, URGN side by side · Screen every company in Pharmaceutical Preparations ↗